← Russell 3000 cross-section

ARDX ARDELYX, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$986m
Revenue TTM
$451m
Net income TTM
$-56m
Free cash flow
$-18m
Composite score
45.2
Sector rank
#2021

Valuation

P / E
EV / EBITDA
EV / sales
2.1
FCF yield
-1.82%
Earnings yield vs 10-yr
-10.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-12.3%
EBITDA margin
-7.1%
ROE
-37.4%
ROIC
-29.8%
Revenue growth
16.8%

Insider activity, last 90 days

Net open-market
$-1.42m
Buyers
0
Sellers
8

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

See “— XPHOZAH became part of the ESRD PPS on January 1, 2025, which means coverage for XPHOZAH for Medicare beneficiaries is not available under Medicare Part D; this resulted in a negative and material impact on our XPHOZAH revenue in 2025; and the continued lack of Medicare Part D coverage for XPHOZAH will result in a materially lower pace of revenue growth as compared to expectations before XPHOZAH became part of the ESRD PPS ” below. …ARDELYX, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →